129 related articles for article (PubMed ID: 33754503)
21. Prognostic Role of Circulating LTBP-2 in Patients With Dilated Cardiomyopathy: A Novel Biomarker Reflecting Extracellular Matrix LTBP-2 Accumulation.
Nishiura K; Yokokawa T; Misaka T; Ichimura S; Tomita Y; Miura S; Shimizu T; Sato T; Kaneshiro T; Oikawa M; Kobayashi A; Yoshihisa A; Takeishi Y
Can J Cardiol; 2023 Oct; 39(10):1436-1445. PubMed ID: 37270166
[TBL] [Abstract][Full Text] [Related]
22. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy.
aus dem Siepen F; Buss SJ; Messroghli D; Andre F; Lossnitzer D; Seitz S; Keller M; Schnabel PA; Giannitsis E; Korosoglou G; Katus HA; Steen H
Eur Heart J Cardiovasc Imaging; 2015 Feb; 16(2):210-6. PubMed ID: 25246502
[TBL] [Abstract][Full Text] [Related]
23. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host.
Szalay G; Sauter M; Haberland M; Zuegel U; Steinmeyer A; Kandolf R; Klingel K
Circ Res; 2009 Apr; 104(7):851-9. PubMed ID: 19246678
[TBL] [Abstract][Full Text] [Related]
24. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Yang C; Qiao S; Song Y; Liu Y; Tang Y; Deng L; Yuan J; Hu F; Yang W
Cardiovasc Pathol; 2019; 43():107150. PubMed ID: 31639652
[TBL] [Abstract][Full Text] [Related]
25. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy.
Timonen P; Magga J; Risteli J; Punnonen K; Vanninen E; Turpeinen A; Tuomainen P; Kuusisto J; Vuolteenaho O; Peuhkurinen K
Int J Cardiol; 2008 Mar; 124(3):293-300. PubMed ID: 17442428
[TBL] [Abstract][Full Text] [Related]
26. Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression.
Nagao K; Inada T; Tamura A; Kajitani K; Shimamura K; Yukawa H; Aida K; Sowa N; Nishiga M; Horie T; Makita T; Ono K; Tanaka M
ESC Heart Fail; 2018 Dec; 5(6):1044-1051. PubMed ID: 30273997
[TBL] [Abstract][Full Text] [Related]
27. Canine Dilated Cardiomyopathy: Diffuse Remodeling, Focal Lesions, and the Involvement of Macrophages and New Vessel Formation.
Gasparini S; Fonfara S; Kitz S; Hetzel U; Kipar A
Vet Pathol; 2020 May; 57(3):397-408. PubMed ID: 32125251
[TBL] [Abstract][Full Text] [Related]
28. Twelve-month kinetics of circulating fibrosis-linked microRNAs (miR-21, miR-29, miR-30, and miR-133a) and the relationship with extracellular matrix fibrosis in dilated cardiomyopathy.
Rubiś P; Totoń-Żurańska J; Kołton-Wróż M; Wołkow P; Pitera E; Wiśniowska-Śmiałek S; Dziewięcka E; Garlitski A; Podolec P
Arch Med Sci; 2022; 18(2):480-488. PubMed ID: 35316894
[TBL] [Abstract][Full Text] [Related]
29. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy.
Yokoseki O; Yazaki Y; Suzuki J; Imamura H; Takenaka H; Isobe M
Jpn Circ J; 2000 May; 64(5):352-7. PubMed ID: 10834450
[TBL] [Abstract][Full Text] [Related]
30. Native T1 Mapping and Extracellular Volume Mapping for the Assessment of Diffuse Myocardial Fibrosis in Dilated Cardiomyopathy.
Nakamori S; Dohi K; Ishida M; Goto Y; Imanaka-Yoshida K; Omori T; Goto I; Kumagai N; Fujimoto N; Ichikawa Y; Kitagawa K; Yamada N; Sakuma H; Ito M
JACC Cardiovasc Imaging; 2018 Jan; 11(1):48-59. PubMed ID: 28624408
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.
Franz M; Berndt A; Neri D; Galler K; Grün K; Porrmann C; Reinbothe F; Mall G; Schlattmann P; Renner A; Figulla HR; Jung C; Küthe F
Int J Cardiol; 2013 Oct; 168(6):5344-51. PubMed ID: 23998545
[TBL] [Abstract][Full Text] [Related]
32. Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age.
Antonov IB; Kozlov KL; Pal'tseva EM; Polyakova OV; Lin'kova NS
Bull Exp Biol Med; 2018 Mar; 164(4):550-553. PubMed ID: 29504111
[TBL] [Abstract][Full Text] [Related]
33. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
34. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.
Wojciechowska C; Romuk E; Nowalany-Kozielska E; Jacheć W
Hellenic J Cardiol; 2017; 58(5):350-359. PubMed ID: 28363768
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers of Collagen Metabolism Are Associated with Left Ventricular Function and Prognosis in Dilated Cardiomyopathy: A Multi-Modal Study.
Raafs AG; Adriaans BP; Henkens MTHM; Verdonschot JAJ; Abdul Hamid MA; Díez J; Knackstedt C; van Empel VPM; Brunner-La Rocca HP; González A; Wildberger JE; Heymans SRB; Hazebroek MR
J Clin Med; 2023 Sep; 12(17):. PubMed ID: 37685762
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
[TBL] [Abstract][Full Text] [Related]
37. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis.
Klappacher G; Franzen P; Haab D; Mehrabi M; Binder M; Plesch K; Pacher R; Grimm M; Pribill I; Eichler HG
Am J Cardiol; 1995 May; 75(14):913-8. PubMed ID: 7733000
[TBL] [Abstract][Full Text] [Related]
38. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography.
Leong DP; Chakrabarty A; Shipp N; Molaee P; Madsen PL; Joerg L; Sullivan T; Worthley SG; De Pasquale CG; Sanders P; Selvanayagam JB
Eur Heart J; 2012 Mar; 33(5):640-8. PubMed ID: 22048681
[TBL] [Abstract][Full Text] [Related]
39. Plasma osteopontin levels, but not its myocardial expression, reflect heart failure severity in recently diagnosed dilated cardiomyopathy.
Podzimkova J; Palecek T; Kuchynka P; Marek J; Danek BA; Jachymova M; Safarikova M; Kalousova M; Zima T; Linhart A
Herz; 2020 Dec; 45(Suppl 1):105-110. PubMed ID: 31289910
[TBL] [Abstract][Full Text] [Related]
40. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio.
Pauschinger M; Knopf D; Petschauer S; Doerner A; Poller W; Schwimmbeck PL; Kühl U; Schultheiss HP
Circulation; 1999 Jun; 99(21):2750-6. PubMed ID: 10351968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
